市場調査レポート
商品コード
910949

ジェネリックがん治療薬の世界市場:分子タイプ、適応症別の分析と予測

Generic Oncology Drugs Market to 2027 - Global Analysis and Forecasts by Molecular Type ; Indication, and Geography

出版日: | 発行: The Insight Partners | ページ情報: 英文 152 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
ジェネリックがん治療薬の世界市場:分子タイプ、適応症別の分析と予測
出版日: 2019年08月16日
発行: The Insight Partners
ページ情報: 英文 152 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のジェネリックがん治療薬(がん治療薬の後発医薬品)市場を調査し、市場の概要、分子タイプ・適応症・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場機会、市場シェア、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査範囲
  • 調査レポートのガイダンス
  • 市場区分

第2章 重要点

第3章 調査方法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 市場情勢

  • 市場概要
  • 専門家の意見
  • PEST分析

第5章 市場力学

  • 市場の成長要因
  • 市場の阻害要因
  • 市場機会
  • 将来動向
  • 影響分析

第6章 世界のジェネリックがん治療薬市場の分析

  • 収益予測と分析
  • 市場分析と予測:地域別
  • 主要企業の市場ポジショニング

第7章 ジェネリックがん治療薬市場の分析と予測:分子タイプ別

  • 概要
  • 市場シェア:分子タイプ別(実績値・予測値)
  • 高分子医薬品
  • 低分子医薬品

第8章 ジェネリックがん治療薬市場の分析と予測:適応症別

  • 概要
  • 市場シェア:適応症別(実績値・予測値)
  • 肺がん
  • 胃がん
  • 大腸がん
  • 乳がん
  • 前立腺癌
  • 肝がん
  • 腎がん
  • 子宮頸癌
  • その他

第9章 ジェネリックがん治療薬市場の分析と予測:地域別

  • 北米市場の収益額と予測:分子タイプ・適応症別
  • 欧州市場の収益額と予測:分子タイプ・適応症別

第10章 アジア太平洋地域のジェネリックがん治療薬市場

  • 概要
  • 収益額と予測:セグメント・国別
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国

第11章 中東・アフリカのジェネリックがん治療薬市場

  • 概要
  • 収益額と予測:セグメント・国別
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第12章 中南米のジェネリックがん治療薬市場

  • 概要
  • 収益額と予測:セグメント・国別
  • ブラジル

第13章 競合情勢

  • 概要
  • 市場の成長戦略
  • 有機成長戦略
  • 無機成長戦略

第14章 主要企業のプロファイル

  • Dr. Reddy's Laboratories Ltd
  • Fresenius Kabi AG
  • Cipla Inc.
  • Mylan N.V.
  • Zydus Cadila
  • Intas Pharmaceuticals
  • Aurobindo Pharma
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH (A Division of Novartis AG)
  • Glenmark
  • Sun Pharmaceutical Industries Ltd.
  • MSN Laboratories

第15章 付録

  • Insight Partnersについて
  • 用語集
図表

LIST OF TABLES

  • Table 1. North America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 2. North America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 3. US Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 4. US Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 5. Canada Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 6. Canada Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 7. Mexico Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 8. Mexico Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 9. Europe Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 10. Europe Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 11. UK Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 12. UK Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 13. Germany Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 14. Germany Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 15. France Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 16. France Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 17. Italy Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 18. Italy Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 19. Spain Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 20. Spain Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 21. Asia Pacific Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 22. Asia Pacific Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 23. Japan Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 24. Japan Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 25. China Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 26. China Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 27. India Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 28. India Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 29. Australia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 30. Australia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 31. South Korea Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 32. South Korea Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 33. Middle East & Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 34. Middle East & Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 35. South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 36. South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 37. Saudi Arabia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 38. Saudi Arabia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 39. UAE Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 40. UAE Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 41. South and Central America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 42. South and Central America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 43. Brazil Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 44. Brazil Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 45. Argentina Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • Table 46. Argentina Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • Table 47. Glossary Of Terms, Generic Oncology Drugs Market

LIST OF FIGURES

  • Figure 1. Generic Oncology Drugs Market Segmentation
  • Figure 2. Generic Oncology Drugs Segmentation, By Region
  • Figure 3. Asia Pacific Generic Oncology Drugs Market, Revenue (US$ Mn), 2018 & 2027
  • Figure 4. Global Generic Oncology Drugs Market By Product, Market Share (%), 2018
  • Figure 5. Global Generic Oncology Drugs Market By Indication, Market Share (%), 2018
  • Figure 6. North America : PEST Analysis
  • Figure 7. Europe: PEST Analysis
  • Figure 8. Asia Pacific PEST Analysis
  • Figure 9. Middle East & Africa PEST Analysis
  • Figure 10. South & Central America PEST Analysis
  • Figure 11. Most Prevalent Forms of Cancers Globally, 2018
  • Figure 12. Comparison of Brand - Name Drugs and Generic Drugs
  • Figure 13. Generic Oncology Drugs Market Impact Analysis of Driver And Restraints
  • Figure 14. Global Generic Oncology Drugs Market - Revenue Forecasts And Analysis - 2018- 2027
  • Figure 15. Global Generic Oncology Drugs Market - By Geography Forecasts And Analysis - 2018- 2027
  • Figure 16. Global Generic Oncology Drugs Market - Market Positioning
  • Figure 17. Global Generic Oncology Drugs Market Share by Molecule Type 2018 & 2027 (%)
  • Figure 18. Large Molecules Market Revenue And Forecasts To 2027 (US$ Mn)
  • Figure 19. Small Molecules Market Revenue And Forecasts To 2027 (US$ Mn)
  • Figure 20. Global Generic Oncology Drugs Market Share by Indication 2018 & 2027 (%)
  • Figure 21. Lung Cancer Market Revenue And Forecasts To 2027 (US$ Mn)
  • Figure 22. Stomach Cancer Market Revenue And Forecasts To 2027 (US$ Mn)
  • Figure 23. Colorectal Cancer Market Revenue And Forecasts To 2027 (US$ Mn)
  • Figure 24. Breast Cancer Market Revenue And Forecasts To 2027 (US$ Mn)
  • Figure 25. Prostate Cancer Market Revenue And Forecasts To 2027 (US$ Mn)
  • Figure 26. Liver Cancer Market Revenue And Forecasts To 2027 (US$ Mn)
  • Figure 27. Kidney Cancer Market Revenue And Forecasts To 2027 (US$ Mn)
  • Figure 28. Cervical Cancer Market Revenue And Forecasts To 2027 (US$ Mn)
  • Figure 29. Others Market Revenue And Forecasts To 2027 (US$ Mn)
  • Figure 30. North America Generic Oncology Drugs Market Revenue Overview, by Country, 2018 (US$ Mn)
  • Figure 31. North America Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 32. North America Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)
  • Figure 33. US Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 34. Canada Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 35. Mexico Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 36. Europe Generic Oncology Drugs Market Revenue Overview, by Country, 2018 (US$ MN)
  • Figure 37. Europe Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 38. Europe Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)
  • Figure 39. UK Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 40. Germany Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 41. France Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 42. Italy Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 43. Spain Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 44. Asia Pacific Generic Oncology Drugs Market Overview, by Country (2017)
  • Figure 45. Asia Pacific Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 46. Asia Pacific Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)
  • Figure 47. Japan Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 48. China Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 49. India Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 50. Australia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 51. South Korea Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 52. Middle East & Africa Generic Oncology Drugs Market Overview, by Country (2017)
  • Figure 53. Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 54. Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)
  • Figure 55. South Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 56. Saudi Arabia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 57. UAE Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 58. South and Central America Generic Oncology Drugs Market Overview, by Country (2017)
  • Figure 59. South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • Figure 60. South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)
  • Figure 61. Brazil Generic Oncology Drugs Market Revenue And Forecasts To 2027 (US$ Mn)
  • Figure 62. Argentina Generic Oncology Drugs Market Revenue And Forecasts To 2027 (US$ Mn)
  • Figure 63. Growth Strategies in the Generic Oncology Drugs Market, 2016-2019
目次
Product Code: TIPRE00006393

The global generic oncology drugs market is expected to reach US$ 36,029.60 Mn in 2027 from US$ 21,200.00 in 2018. The market is estimated to grow with a CAGR of 6.3% from 2019-2027.

Factors such as, growing cancer prevalence across the globe, new product launches and benefits offered by generic drugs are boosting the market over the years. In addition, the growing pharmaceutical industry in developing countries are likely to have a positive impact on the growth of the market in the coming years.

Generic drugs are copies of branded drugs. Their pharmacological effects are similar to the branded counterparts. Generic drugs are cost effective as the manufacturers have not invested in the development and marketing of the new drug. When a drug patent expires, other manufacturers apply for FDA approval in order to manufacture and sell the product. Hence generic drugs are cheaper than branded drugs. The generic drug have exactly the same effects, dosage, side effects, route of administration, safety, risks, and strength as the original branded drug. Generic drugs are important in oncology as some anticancer drugs are only offered as generics. In most of the cases like, children with acute lymphoblastic leukemia or women patients with early-stage breast cancer are treated with generics. Generic drugs are extensively used in supportive care. The most significant benefit of using generic drugs is the cost, which is up to 85% less than that of a branded drugs. Thus, these benefits offered by generic drugs is likely to enhance the market growth during the forecast period.

The global generic oncology drugs market, based on the indication was segmented into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, kidney cancer, cervical cancer, others. In 2018, the lung cancer segment held the largest share of the market, by indication. The highest share of lung cancer segment attributes to the high prevalence of patients suffering with the lung cancer that can be treated with generic oncology drugs.

Some of the major primary and secondary sources included in the report for the Generic Oncology Drugs Market are the World Health Organization, British Generics Manufacturers Association, Centers for Disease Control and Prevention, Cancer Association of South Africa, Italian Association for Cancer Research, American Cancer Society, Indian Brand Equity Foundation, and others.

TABLE OF CONTENTS

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Global Generic Oncology Drugs Market - By Molecule Type
    • 1.3.2 Global Generic Oncology Drugs Market - By Application
    • 1.3.3 Global Generic Oncology Drugs Market - By Geography

2. Global Generic Oncology Drugs Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Global Generic Oncology Drugs- Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America PEST Analysis
    • 4.2.2 Europe PEST Analysis
    • 4.2.3 Asia Pacific - PEST Analysis
    • 4.2.4 Middle East & Africa- PEST Analysis
    • 4.2.5 South & Central America - PEST Analysis
  • 4.3 Expert Opinions

5. Global Generic Oncology Drugs Market - Key Industry Dynamics

  • 5.1 Key Market Drivers
    • 5.1.1 Growing Cancer Prevalence Across The Globe
    • 5.1.2 New Drug Launches
    • 5.1.3 Benefits Offered By Generic Drugs
  • 5.2 Key Market Restraints
    • 5.2.1 Pricing Pressure
  • 5.3 Key Market Opportunities
    • 5.3.1 Growing Pharmaceutical Industry in Emerging Economies
  • 5.4 Future Trends
    • 5.4.1 Inclination Towards Personalized Medicine
  • 5.5 Impact Analysis

6. Generic Oncology Drugs Market - Global Analysis

  • 6.1 Global Generic Oncology Drugs Market Revenue Forecasts And Analysis
  • 6.2 Global Generic Oncology Drugs Market, By Geography - Forecasts And Analysis
  • 6.3 Market Positioning of Key Players

7. Generic Oncology Drugs Market Analysis And Forecasts To 2027 - Molecule Type

  • 7.1 Overview
  • 7.2 Global Generic Oncology Drugs Market Share by Molecule Type 2018 & 2027 (%)
  • 7.3 Large Molecules Market
    • 7.3.1 Overview
    • 7.3.2 Large Molecules Market Revenue and Forecast to 2027 (US$ Mn)
  • 7.4 Small Molecules Market
    • 7.4.1 Overview
    • 7.4.2 Small Molecules Market Revenue and Forecast to 2027 (US$ Mn)

8. Generic Oncology Drugs Market Analysis And Forecasts To 2027 - Indication

  • 8.1 Overview
  • 8.2 Global Generic Oncology Drugs Market Share by Indication 2018 & 2027 (%)
  • 8.3 Lung Cancer
    • 8.3.1 Overview
    • 8.3.2 Lung Cancer Market Revenue and Forecast to 2027 (US$ Mn)
  • 8.4 Stomach Cancer
    • 8.4.1 Overview
    • 8.4.2 Stomach Cancer Market Revenue and Forecast to 2027 (US$ Mn)
  • 8.5 Colorectal Cancer
    • 8.5.1 Overview
    • 8.5.2 Colorectal Cancer Market Revenue and Forecast to 2027 (US$ Mn)
  • 8.6 Breast Cancer
    • 8.6.1 Overview
    • 8.6.2 Breast Cancer Market Revenue and Forecast to 2027 (US$ Mn)
  • 8.7 Prostate Cancer
    • 8.7.1 Overview
    • 8.7.2 Prostate Cancer Market Revenue and Forecast to 2027 (US$ Mn)
  • 8.8 Liver Cancer
    • 8.8.1 Overview
    • 8.8.2 Liver Cancer Market Revenue and Forecast to 2027 (US$ Mn)
  • 8.9 Kidney Cancer
    • 8.9.1 Overview
    • 8.9.2 Kidney Cancer Market Revenue and Forecast to 2027 (US$ Mn)
  • 8.10 Cervical Cancer
    • 8.10.1 Overview
    • 8.10.2 Cervical Cancer Market Revenue and Forecast to 2027 (US$ Mn)
  • 8.11 Others
    • 8.11.1 Overview
    • 8.11.2 Others Market Revenue and Forecast to 2027 (US$ Mn)

9. Generic Oncology Drugs Market Revenue and Forecasts to 2027 - Geographical Analysis

  • 9.1 North America Generic Oncology Drugs Market Revenue And Forecasts To 2027
    • 9.1.1 North America Generic Oncology Drugs market Revenue and Forecasts to 2027 (US$ Mn)
  • 9.2 North America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • 9.3 North America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
    • 9.3.1 North America Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)
    • 9.3.2 US Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
      • 9.3.2.1 US Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
      • 9.3.2.2 US Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
      • 9.3.2.3 US Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
    • 9.3.3 Canada Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
      • 9.3.3.1 Canada Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 9.3.4 Canada Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
    • 9.3.5 Canada Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
    • 9.3.6 Mexico Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
      • 9.3.6.1 Mexico Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 9.3.7 Mexico Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
    • 9.3.8 Mexico Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • 9.4 Europe Generic Oncology Drugs Market Revenue And Forecasts To 2027
    • 9.4.1 Europe Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • 9.5 Europe Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • 9.6 Europe Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
    • 9.6.1 Europe Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)
    • 9.6.2 UK Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
      • 9.6.2.1 UK Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 9.6.3 UK Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
    • 9.6.4 UK Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
    • 9.6.5 Germany Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
      • 9.6.5.1 Germany Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 9.6.6 Germany Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
    • 9.6.7 Germany Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
    • 9.6.8 France Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
      • 9.6.8.1 France Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 9.6.9 France Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
    • 9.6.10 France Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
    • 9.6.11 Italy Generic oncology drugs market Revenue and Forecasts to 2027 (US$ Mn)
      • 9.6.11.1 Italy Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 9.6.12 Italy Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
    • 9.6.13 Italy Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
    • 9.6.14 Spain Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
      • 9.6.14.1 Spain Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 9.6.15 Spain Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
    • 9.6.16 Spain Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

10. Asia Pacific Generic Oncology Drugs Market Revenue and Forecasts to 2027

  • 10.1 Overview
  • 10.2 Asia Pacific Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • 10.3 Asia Pacific Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • 10.4 Asia Pacific Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • 10.5 Asia Pacific Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)
  • 10.6 Japan Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 10.6.1 Japan Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 10.6.2 Japan Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
    • 10.6.3 Japan Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • 10.7 China Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 10.7.1 China Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 10.7.2 South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
    • 10.7.3 China Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • 10.8 India Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 10.8.1 India Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 10.8.2 India Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
    • 10.8.3 India Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • 10.9 Australia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 10.9.1 Australia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 10.9.2 Australia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
    • 10.9.3 Australia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • 10.10 South Korea Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 10.10.1 South Korea Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 10.10.2 South Korea Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
    • 10.10.3 South Korea Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

11. Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027

  • 11.1 Overview
  • 11.2 Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • 11.3 Middle East & Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • 11.4 Middle East & Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • 11.5 Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)
  • 11.6 South Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 11.6.1 South Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 11.6.2 South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
    • 11.6.3 South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • 11.7 Saudi Arabia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 11.7.1 Saudi Arabia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 11.7.2 Saudi Arabia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
    • 11.7.3 Saudi Arabia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • 11.8 UAE Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 11.8.1 UAE Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 11.8.2 UAE Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
    • 11.8.3 UAE Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

12. South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027

  • 12.1 Overview
  • 12.2 South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
  • 12.3 South and Central America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
  • 12.4 South and Central America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
  • 12.5 South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)
  • 12.6 Brazil Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
      • 12.6.1.1 Brazil Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 12.6.2 Brazil Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
    • 12.6.3 Brazil Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
    • 12.6.4 Argentina Generic Oncology Drugs Market
      • 12.6.4.1 Argentina Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
    • 12.6.5 Argentina Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
    • 12.6.6 Argentina Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

13. Generic Oncology Drugs Market - Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in the Generic Oncology Drugs Market, 2016-2019
  • 13.3 Organic Growth Strategies
  • 13.4 Inorganic Growth Strategies

14. Generic Oncology Drugs Market-Key Company Profiles

  • 14.1 Dr. Reddy's Laboratories Ltd
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Financial Overview
    • 14.1.4 Product Portfolio
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Fresenius Kabi AG
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Financial Overview
    • 14.2.4 Product Portfolio
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Cipla Inc.
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Financial Overview
    • 14.3.4 Product Portfolio
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 Mylan N.V.
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Financial Overview
    • 14.4.4 Product Portfolio
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 Zydus Cadila
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Financial Overview
    • 14.5.4 Product portfolio
    • 14.5.5 SWOT Analysis
    • 14.5.6 KEY DEVELOPMENTS
  • 14.6 Intas Pharmaceuticals
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Financial Information
    • 14.6.4 Product Portfolio
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 Aurobindo Pharma
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Financial Overview
    • 14.7.4 Product Portfolio
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 Teva Pharmaceutical Industries Ltd.
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Financial Overview
    • 14.8.4 Product Portfolio
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 Sandoz International GmbH (A Division of Novartis AG)
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Financial Overview
    • 14.9.4 Product Portfolio
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments
  • 14.10 Glenmark
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Financial Overview
    • 14.10.4 Product Portfolio
    • 14.10.5 SWOT Analysis
    • 14.10.6 Key Developments
  • 14.11 Sun Pharmaceutical Industries Ltd.
    • 14.11.1 Key Facts
    • 14.11.2 Business Description
    • 14.11.3 Financial Overview
    • 14.11.4 Product Portfolio
    • 14.11.5 SWOT Analysis
    • 14.11.6 Key Developments
  • 14.12 MSN Laboratories
    • 14.12.1 Key Facts
    • 14.12.2 Business Description
    • 14.12.3 Financial Overview
    • 14.12.4 Product Portfolio
    • 14.12.5 SWOT Analysis
    • 14.12.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners
  • 15.2 Glossary Of Terms